NCT05806931 2026-03-18
SCOTI
Rutgers, The State University of New Jersey
Phase 2 Recruiting
Clinical Trials
25 trialsNCT06607458 2026-03-13
DEL-LIVER
Delcath Systems Inc.
Phase 2 Recruiting
NCT07011550 2026-03-11
Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT05343013 2026-03-06
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03686488 2026-03-02
TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT07146646 2026-02-19
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT05062889 2026-02-03
ERASE-CRC
Gruppo Oncologico del Nord-Ovest
Phase 2 Suspended
NCT03844620 2026-01-09
Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06856837 2025-12-12
- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT04417699 2025-12-10
SHORT
Providence Health & Services
Phase 2 Completed
NCT06245356 2025-12-10
TRIFLUOX-DP
UNICANCER
Phase 2 Recruiting
NCT04042714 2025-11-04
TAS-102 NEC
Baylor Research Institute
Phase 2 Terminated
NCT07212933 2025-10-08
RAK in GC
Chinese PLA General Hospital
Phase 2 Recruiting
NCT04489173 2025-09-19
TIBET
Borstkanker Onderzoek Groep
Phase 2 Active not recruiting
NCT06887218 2025-08-27
5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
The Methodist Hospital Research Institute
Phase 2 Recruiting
NCT07142421 2025-08-26
A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma
First Affiliated Hospital of Zhejiang University
Phase 2 Active not recruiting
NCT07116577 2025-08-11
Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC
Jinan Central Hospital
Phase 2 Not yet recruiting
NCT07090031 2025-07-29
Perioperative Treatment With TAS-102 in Combination With Oxaliplatin for Locally Advanced Rectal Cancer
Qingdao Central Hospital
Phase 2 Active not recruiting
NCT07085169 2025-07-25
Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC
Ruijin Hospital
Phase 2 Recruiting
NCT04923529 2025-07-18
TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma
The University of Hong Kong
Phase 2 Completed
NCT07071844 2025-07-17
BETWEEN
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Not yet recruiting
NCT05854498 2025-06-12
Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT05481463 2025-05-28
Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer
Sun Yat-sen University
Phase 2 Completed
NCT05965531 2025-04-29
TASLARC
Sun Yat-sen University
Phase 2 Recruiting
NCT04450836 2025-03-30
SOREGATT
UNICANCER
Phase 2 Terminated